Tislelizumab extended OS compared with chemotherapy for patients with previously treated advanced esophageal squamous cell carcinoma, according to topline data released by the agent’s manufacturer.
Tislelizumab (BGB-A317, BeiGene) is humanized immunoglobulin G4 anti-PD-1 monoclonal antibody designed to minimize binding to Fc gamma receptors on macrophages.
The randomized phase 3 RATIONALE 302 trial included 512 patients from North America, Europe or Asia with advanced unresectable or metastatic esophageal squamous cell carcinoma who received prior systemic treatment.
Researchers assigned patients to tislelizumab or the investigator’s choice of paclitaxel, docetaxel or irinotecan. The trial met its primary endpoint, with results showing a statistically significant improvement in OS with tislelizumab in the intention-to-treat population. Tislelizumab exhibited a safety profile consistent with prior reports. Researchers observed no new safety signals.
“Esophageal cancer represents a significant unmet medical need with rapid progression and high mortality,” Lin Shen, MD, vice president of clinical oncology at Beijing Cancer Hospital and lead investigator for the RATIONALE 302 trial, said in a BeiGene-issued press release. “Recent years have seen a paradigm shift in advanced [esophageal squamous cell carcinoma] treatment from chemotherapy and radiation to immunotherapy. The positive topline results from the RATIONALE 302 trial demonstrated that tislelizumab may offer a new treatment option for those living with this devastating disease and bring hope to patients and their families.”
Complete results of the trial will be submitted for presentation at a medical conference and shared with health authorities.
“This is our fourth positive phase 3 readout for tislelizumab and the first from our large phase 3 program in gastrointestinal cancers,” Yong (Ben) Ben, MD, chief medical officer for immuno-oncology with BeiGene, said in the release. “With our ongoing evaluation of tislelizumab across multiple tumor types, we are working to provide clinical evidence and bring this potentially differentiated anti-PD-1 antibody to far more patients around the world.”
more recommended stories
ChatGPT Excels in Medical Summaries, Lacks Field-Specific RelevanceIn a recent study published in.
Study finds automated decision minimizes high-risk medicine combinations in ICU patientsA multicenter study coordinated by Amsterdam.
Study Discovers Connection Between Omicron Infection and Brain Structure Changes in MenA recent study in the JAMA.
Advancing COPD Prognosis: Deep Learning ModelsResearchers conducted a meta-analysis in a.
4 in 1 Test for Swine Flu, COVID-19, RSV, and InfluenzaIn the United Kingdom, the first.
Innovative Zika Virus Defense: Needle-Free Vaccine PatchTo protect individuals from the potentially.
Social Media Impact on Mental Health TreatmentAccording to research, social media might.
Unveiling the Impact of Whole Grain Consumption on Slowing Memory Decline in Black PopulationsConsuming a diet rich in whole.
$1 Cancer Treatment: Engineered Bacteria BreakthroughWhat if a single one-dollar dose.
Pfizer COVID Booster: Half-Dose, Reduced Side EffectsIn a recent report in The.
Leave a Comment